by 
The anti-neprilysin market is witnessing significant growth over the past few years owing to rising prevalence of cardiovascular diseases and kidney problems globally. Neprilysin is an enzyme which breaks down natriuretic peptides that regulate blood pressure and sodium balance in the body. Anti-neprilysin drugs inhibit this enzyme and help control blood pressure. Some key advantages of anti-neprilysin drugs are reduced risk of cardiovascular events, improved kidney function, and lowered hospitalization rates in patients with heart failure. With rising geriatric population worldwide, the need for effective treatment options for controlling blood pressure and related co-morbidities is increasing steadily.
The Global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd.
Key opportunities in the market include establishing collaborative R&D for developing combination therapies and exploring new indications. Several pipeline drugs are under clinical trials aimed at improving cardiovascular outcomes.
Technological advancements include development of orally administrated anti-neprilysin drugs with prolonged half-life and minimal side effects compared to intravenous formulations. Companies are also working on neprilysin-targeting gene therapies.
Market drivers
The growing geriatric population prone to developing hypertension, heart failure and kidney diseases is a major driver for the anti-neprilysin market. As per estimates, over 1.5 billion people worldwide currently have hypertension. Rising healthcare expenditures on managing cardiovascular risk factors in developing nations will also support market growth over the forecast period.
Current Challenges in Anti-Neprilysin Market
The Anti-Neprilysin market is still in a nascent stage and faces multiple challenges. High development costs and regulatory hurdles have deterred many small players from venturing into this market. Also, the lack of expertise and advanced research infrastructure pose significant challenges, especially for new entrants. Changing reimbursement policies also continue to affect the profit margins of existing players. Further, the absence of combinational drug therapies and lack of awareness are impeding the growth of this market.
SWOT Analysis
Strength: Emerging clinical data demonstrating the efficacy of Anti-Neprilysin drugs in treating HF. Several pharmaceutical majors investing significantly in R&D to develop novel drug candidates.
Weakness: High failure rate of drug candidates in clinical trials. Safety concerns over certain side effects like angioedema.
Opportunity: Rising geriatric population susceptible to HF presents a huge patient pool. Combination therapies hold promise to optimize outcomes.
Threats: Patent expiries of major drugs resulting in lower prices and revenues. Stiff competition from alternative treatment options.
In terms of value, North America holds the major share in the global Anti-Neprilysin market due to growing awareness about HF, advanced healthcare facilities and large patient pool. Western Europe is the second largest regional market owing to supportive regulatory environment and healthcare reimbursement policies in countries like UK, Germany, France and Italy.
The Asia Pacific region is expected to witness the highest growth in the Anti-Neprilysin market during the forecast period. Factors such as increasing healthcare spending, large untapped opportunities, growing cases of HF and improving access to diagnostic and treatment options will drive the APAC market.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
